At the courtesy of the speaker, presentation slides are available from Optivia.
Contact Optivia for details.
Organizer: Optivia Biotechnology Inc.
Time: Tue, July 18, 2017 10:00 AM - 11:30 AM PDT
Clearance is a pharmacokinetic parameter that plays a pivotal role in determining the dose that is required to modulate biological targets in humans. Its accurate prediction is a prerequisite for improving our ability to test new mechanisms of action for new molecular entities. Introduced by Sirianni and Pang, the Extended Clearance Concept shifted our understanding of drug clearance from being considered an additive process to rather an interplay of inputs, namely intrinsic passive clearance, active hepatic uptake, metabolic, and biliary clearance. This webinar discusses the extended clearance concept, its principles and utility in predicting rate determining steps of drug clearance, and the impact of enzyme/transporter inhibition or genetic variation on overall compound clearance, systemic and tissue exposures. It also outlines areas where poor understanding of this principle would undermine our ability to successfully predict clearance and other relevant parameters of interest, such as drug-drug interactions, tissue exposure, and pharmacodynamics profiles. Specifically, cases studies are used to increase the awareness of common mistakes to avoid in order to improve data interpretation and prediction accuracy of clearance and other PK/PD parameters. Additionally, the webinar shares questions that are worth considering in order to successfully use this principle.
Ayman F. El-Kattan
B. Pharm., Ph.D., Associate Research Fellow, Pfizer Inc. Cambridge Laboratories
Dr. Ayman El-Kattan is an Associate Research Fellow at the Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Inc. Cambridge Laboratories. He earned his bachelor degree in pharmacy with distinction from the University of Jordan, and a Ph.D. in Basic Pharmaceutical Sciences at the University of South Carolina in the US. His main research interests are focused on understanding the role of transporters in influencing drug disposition and oral absorption. His research also involves studying the utility of physiologically based pharmacokinetic modeling (PBPK) tools in projecting drug disposition and drug-drug interaction liabilities in man for new molecular entities (NME). He is also an Adjunct Professor at the College of Pharmacy-University of Rhode Island in Rhode Island, US, where he lectures in the graduate-level pharmacokinetic courses and serves as external advisor on dissertation committees. Dr. El-Kattan is a reviewer for several journals and is an active member of the American Association of Pharmaceutical Scientists (AAPS) and serves on the executive committee of the Drug Transporter focus group. He has been invited to speak over 50 times at national and international conferences and meetings, and has published over 100 papers in peer-reviewed journals, book chapters and proceedings. Recently, Dr. El-Kattan published a book titled Oral Bioavailability Assessment, Basics and Strategies for Drug Discovery and Development, by Wiley.